Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety study of anumigilimab in adults with sickle cell disease
NL-OMON61083Phase 2Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of anumigilimab in sickle cell disease (SCD), sponsored by CSL Behring. Primary endpoints: Treatment-emergent adverse events, Adverse events of special interest and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
anumigilimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON61083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61083.